Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties.

Abstract

OBJECTIVES:

The aim of this study is to evaluate the effects of alogliptin on metabolic profiles in relation to those of glycemic control.

PATIENTS AND METHODS:

Treatment naïve subjects with type 2 diabetes received 12.5-25 mg/d alogliptin monotherapy (n = 59). A novel parameter called A1c index was used to assess the glycemic efficacy. The subjects were divided into three groups according to this index; super-responders, average responders and poor-responders. At 3 months, levels of the metabolic parameters were compared with those at baseline between super-responders (n = 20) and poor-responders (n = 21).

RESULTS:

At baseline, total cholesterol, non-high density lipoprotein cholesterol and atherogenic index were significantly higher in super-responders than poor-responders. At 3 months, significant increases of beta-cell function (HOMA-B) and decreases of insulin resistance (HOMA-R) or these atherogenic lipids were observed in super-responders, while significant increases of HOMA-R were observed in poor-responders. Significant correlations were observed between A1c index and the changes of these atherogenic lipids. In super-responders, significant correlations were observed between the changes (Δ) of glycemic parameters (A1c index or fasting blood sugar) and ΔHOMA-R and/or ΔHOMA-B, while in poor-responders, significant correlations were observed between ΔHOMA-R and ΔHOMA-B. Lean subjects gained weight and the changes of body mass index had significant negative correlations with A1c index.

CONCLUSIONS:

These results indicate that (1) glucose lowering efficacy of alogliptin is closely linked to atherogenic lipids. (2) alogliptin can down-regulate atherogenic lipids. (3) glycemic efficacy of alogliptin appears to be determined by the balance of its capacity in modulating insulin resistance and beta-cell function.

• Authors: Eiji Kutoh, Noriko Kaneoka, Mitsuru Hirate
• Journal: Endocrine research (Endocr Res) Vol. 40 Issue 2 Pg. 88-96 ( 2015) ISSN: 1532-4206 [Electronic] England
• PMID: 25208188 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Blood Glucose
• Dipeptidyl-Peptidase IV Inhibitors
• Glycated Hemoglobin A
• Lipids
• Piperidines
• Uracil
• alogliptin

Topics

• Adult
• Aged
• Atherosclerosis (prevention & control)
• Blood Glucose (drug effects, metabolism)
• Diabetes Mellitus, Type 2 (blood, complications, drug therapy)
• Diabetic Angiopathies (prevention & control)
• Dipeptidyl-Peptidase IV Inhibitors (adverse effects, therapeutic use)
• Female
• Glycated Hemoglobin (analysis)
• Humans
• Insulin Resistance
• Insulin-Secreting Cells (drug effects, physiology)
• Lipids (blood)
• Male
• Middle Aged
• Piperidines (adverse effects, therapeutic use)
• Uracil (adverse effects, analogs & derivatives, therapeutic use)